Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 138

1.

Influence of Alzheimer disease family history and genetic risk on cognitive performance in healthy middle-aged and older people.

Donix M, Ercoli LM, Siddarth P, Brown JA, Martin-Harris L, Burggren AC, Miller KJ, Small GW, Bookheimer SY.

Am J Geriatr Psychiatry. 2012 Jul;20(7):565-73. doi: 10.1097/JGP.0b013e3182107e6a.

2.

Perceived loss of memory ability and cerebral metabolic decline in persons with the apolipoprotein E-IV genetic risk for Alzheimer disease.

Ercoli L, Siddarth P, Huang SC, Miller K, Bookheimer SY, Wright BC, Phelps ME, Small G.

Arch Gen Psychiatry. 2006 Apr;63(4):442-8.

PMID:
16585474
3.

APOE and cognitive decline in preclinical Alzheimer disease and non-demented aging.

Bunce D, Fratiglioni L, Small BJ, Winblad B, Bäckman L.

Neurology. 2004 Sep 14;63(5):816-21.

PMID:
15365129
4.

APOE genotype, memory test performance, and the risk of Alzheimer's disease in the Canadian Study of Health and Aging.

Klages JD, Fisk JD, Rockwood K.

Dement Geriatr Cogn Disord. 2003;15(1):1-5.

PMID:
12457072
5.

The APOE epsilon4 allele is associated with decline on delayed recall performance in community-dwelling older adults.

O'Hara R, Yesavage JA, Kraemer HC, Mauricio M, Friedman LF, Murphy GM Jr.

J Am Geriatr Soc. 1998 Dec;46(12):1493-8.

PMID:
9848808
6.

Apolipoprotein E and cognitive performance: a meta-analysis.

Small BJ, Rosnick CB, Fratiglioni L, Bäckman L.

Psychol Aging. 2004 Dec;19(4):592-600.

PMID:
15584785
7.

Apolipoprotein E genotype is not associated with cognitive impairment in older adults with bipolar disorder.

Kerr DS, Stella F, Radanovic M, Aprahamian I, Bertollucci PH, Forlenza OV.

Bipolar Disord. 2016 Feb;18(1):71-7. doi: 10.1111/bdi.12367. Epub 2016 Feb 15.

PMID:
26877211
8.

Apolipoprotein E epsilon4 allele and lorazepam effects on memory in high-functioning older adults.

Pomara N, Willoughby L, Wesnes K, Greenblatt DJ, Sidtis JJ.

Arch Gen Psychiatry. 2005 Feb;62(2):209-16.

PMID:
15699298
9.

Family history of Alzheimer disease predicts hippocampal atrophy in healthy middle-aged adults.

Okonkwo OC, Xu G, Dowling NM, Bendlin BB, Larue A, Hermann BP, Koscik R, Jonaitis E, Rowley HA, Carlsson CM, Asthana S, Sager MA, Johnson SC.

Neurology. 2012 May 29;78(22):1769-76. doi: 10.1212/WNL.0b013e3182583047. Epub 2012 May 16.

10.

Predictive utility of apolipoprotein E genotype for Alzheimer disease in outpatients with mild cognitive impairment.

Devanand DP, Pelton GH, Zamora D, Liu X, Tabert MH, Goodkind M, Scarmeas N, Braun I, Stern Y, Mayeux R.

Arch Neurol. 2005 Jun;62(6):975-80.

PMID:
15956169
11.

Longitudinal changes in cognition and behavior in asymptomatic carriers of the APOE e4 allele.

Caselli RJ, Reiman EM, Osborne D, Hentz JG, Baxter LC, Hernandez JL, Alexander GG.

Neurology. 2004 Jun 8;62(11):1990-5.

PMID:
15184602
12.

Interaction of Cigarette Smoking History With APOE Genotype and Age on Amyloid Level, Glucose Metabolism, and Neurocognition in Cognitively Normal Elders.

Durazzo TC, Mattsson N, Weiner MW; Alzheimer’s Disease Neuroimaging Initiative..

Nicotine Tob Res. 2016 Feb;18(2):204-11. doi: 10.1093/ntr/ntv075. Epub 2015 Apr 6.

PMID:
25847292
13.

Altered PET functional brain responses in cognitively intact elderly persons at risk for Alzheimer disease (carriers of the epsilon4 allele).

Scarmeas N, Habeck C, Anderson KE, Hilton J, Devanand DP, Pelton GH, Tabert MH, Flynn J, Park A, Ciappa A, Tycko B, Stern Y.

Am J Geriatr Psychiatry. 2004 Nov-Dec;12(6):596-605.

14.

Apolipoprotein epsilon4 and neuropsychological performance in Alzheimer's disease and vascular dementia.

McGuinness B, Carson R, Barrett SL, Craig D, Passmore AP.

Neurosci Lett. 2010 Oct 8;483(1):62-6. doi: 10.1016/j.neulet.2010.07.063. Epub 2010 Aug 1.

PMID:
20678545
15.

Individual growth curve analysis of APOE epsilon 4-associated cognitive decline in Alzheimer disease.

Hoyt BD, Massman PJ, Schatschneider C, Cooke N, Doody RS.

Arch Neurol. 2005 Mar;62(3):454-9.

PMID:
15767511
16.

Influence of cognitive status, age, and APOE-4 genetic risk on brain FDDNP positron-emission tomography imaging in persons without dementia.

Small GW, Siddarth P, Burggren AC, Kepe V, Ercoli LM, Miller KJ, Lavretsky H, Thompson PM, Cole GM, Huang SC, Phelps ME, Bookheimer SY, Barrio JR.

Arch Gen Psychiatry. 2009 Jan;66(1):81-7. doi: 10.1001/archgenpsychiatry.2008.516.

17.

Impact of APOE status on cognitive maintenance in healthy elderly persons.

Zehnder AE, Bläsi S, Berres M, Monsch AU, Stähelin HB, Spiegel R.

Int J Geriatr Psychiatry. 2009 Feb;24(2):132-41. doi: 10.1002/gps.2080.

PMID:
18615849
18.

Parental history of Alzheimer disease associated with lower plasma apolipoprotein E levels.

van Vliet P, Westendorp RG, Eikelenboom P, Comijs HC, Frölich M, Bakker E, van der Flier W, van Exel E.

Neurology. 2009 Sep 1;73(9):681-7. doi: 10.1212/WNL.0b013e3181b59c2e.

19.

Hypometabolism in Alzheimer-affected brain regions in cognitively healthy Latino individuals carrying the apolipoprotein E epsilon4 allele.

Langbaum JB, Chen K, Caselli RJ, Lee W, Reschke C, Bandy D, Alexander GE, Burns CM, Kaszniak AW, Reeder SA, Corneveaux JJ, Allen AN, Pruzin J, Huentelman MJ, Fleisher AS, Reiman EM.

Arch Neurol. 2010 Apr;67(4):462-8. doi: 10.1001/archneurol.2010.30.

20.

Cerebrovascular risk factors and preclinical memory decline in healthy APOE ε4 homozygotes.

Caselli RJ, Dueck AC, Locke DE, Sabbagh MN, Ahern GL, Rapcsak SZ, Baxter LC, Yaari R, Woodruff BK, Hoffman-Snyder C, Rademakers R, Findley S, Reiman EM.

Neurology. 2011 Mar 22;76(12):1078-84. doi: 10.1212/WNL.0b013e318211c3ae. Epub 2011 Feb 16.

Supplemental Content

Support Center